secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001193125-25-118805
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX nets $93.4M in underwritten common stock offering; 76.9M shares at $1.30
-------------------------------------------------------------------------------

- Sold 76,923,076 shares of common stock at $1.30/share, generating ~$93.4M in net proceeds after underwriting discounts and expenses.
- Proceeds to be used for research and development, general corporate purposes, and working capital.
- Underwriting syndicate led by Jefferies and Piper Sandler & Co.
- Offering closed on May 13, 2025; shares issued under effective shelf registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525118805/0001193125-25-118805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525118805/d53772d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-118805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer